Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Helix BioPharmaHBPCF 28 EV-to-EBIT is -31.65 as of Jul. 15, 2026. GuruFocus rates HBPCF with a GF Score™ of 28/100. Among 371 Biotechnology companies, Helix BioPharma ranks worse than 269541.51% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Helix BioPharma's Enterprise Value for the quarter that ended in Apr. 2026 was $130.33 Mil.
Helix BioPharma's EBIT for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.38 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Helix BioPharma EV-to-EBIT Related Terms
Helix BioPharma EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Helix BioPharma's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Helix BioPharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Helix BioPharma EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Helix BioPharma's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Helix BioPharma's EV-to-EBIT falls into.
Helix BioPharma's current Enterprise Value is $75.45 Mil.
Helix BioPharma's EBIT for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.38 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Helix BioPharma (HBPCF) has a EV-to-EBIT of -31.65 as of Jul. 15, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Helix BioPharma and its competitors. According to the industry distribution chart, Helix BioPharma ranks #999999 out of 371 companies in the Biotechnology industry.
Is Helix BioPharma's EV-to-EBIT too high?
Helix BioPharma's current EV-to-EBIT is -31.65. Based on the distribution chart, Helix BioPharma ranks #999999 out of 371 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Helix BioPharma has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Helix BioPharma's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Helix BioPharma ranks #999999 out of 371 companies for EV-to-EBIT. This places Helix BioPharma in the lower half of its industry. The industry median EV-to-EBIT is 13.76. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 13.76, based on 371 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Helix BioPharma and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 13.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Helix BioPharma's current EV-to-EBIT is -31.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helix BioPharma stock overvalued right now?
Helix BioPharma (HBPCF) has a current EV-to-EBIT of -31.65. The current EV-to-EBIT is -31.65. Helix BioPharma's overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Helix BioPharma (HBPCF), the current EV-to-EBIT is -31.65 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Helix BioPharma Corp is a clinical-stage biopharmaceutical company developing therapies in immune-oncology focused on cancer prevention and treatment. The Company is developing a proprietary platform of bio-conjugates targeting hard-to-treat solid tumors over-expressing CEACAM6, including Tumor Defense Breaker, L-DOS47, and three CEACAM6-specific antibody-drug conjugates. Its pre-IND candidates include LEUMUNA, an oral immune checkpoint modulator for hematological malignancies, and GEMCEDA, an oral prodrug of gemcitabine for solid tumors.
28GF Score
Get the complete analysis for HBPCF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HBPCF has been successfully added to your 
